Stockadora

8-K filings / November 18, 2026

Phathom Pharmaceuticals, Inc.: A change of officers or directors

Phathom Pharmaceuticals, Inc. filed a current report (Form 8-K) with the SEC on November 18, 2026. It reports a change of officers or directors.

AI-written from the facts below

In plain English

Robert Breedlove will leave the role of Vice President, Finance, effective December 4, 2026. This change is reported under Item 5.02 of Form 8-K, which covers directors and senior officers who leave or are appointed.

What each sentence states
“Robert Breedlove will leave the role of Vice President, Finance, effective December 4, 2026.”
  • Item 5.02: Robert Breedlove leaves the role of Vice President, Finance, effective December 4, 2026.
“This change is reported under Item 5.02 of Form 8-K, which covers directors and senior officers who leave or are appointed.”
  • Item 5.02 of Form 8-K covers directors and senior officers who leave or are appointed.
  • Item 5.02: Robert Breedlove leaves the role of Vice President, Finance, effective December 4, 2026.
Written by an AI model from the facts on this page only; code and a second model checked every sentence against them.

Item 5.02

Officers and directors

  • Leaves Robert Breedlove, Vice President, FinanceEffective December 4, 2026 From the filing
    Source
    “On November 12, 2026, Robert Breedlove, Vice President, Finance and principal accounting officer, of Phathom Pharmaceuticals, Inc. (the “Company”) notified the Company of his decision to resign from the Company, effective December 4, 2026.”
    Found by an AI model; the quote is checked word for word against the filing.
Not investment advice.Read the filing on SEC.gov

Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.